About 3D Medicines
3D Medicines is a clinical-stage biotechnology company focused on the development of differentiated next-generation immuno-oncology drugs for cancer patients. Our lead compound, the world’s first subcutaneously administered PD-L1 antibody envafolimab (KN035), is currently under clinical development in the United States, China and Japan with initial BLA submission in China expected in early 2020. We are building our pipeline targeting major indications using combination strategy, either with in-house assets or in collaboration with partners around the world. With a professional team in China and the US, we are capable of conducting global clinical development and registration.